Oppenheimer analyst Hartaj Singh raised the firm’s price target on Regeneron to $950 from $900 and keeps an Outperform rating on the shares. Regeneron’s EPS and sales numbers were significantly above the firm’s estimates, and provided color around the Eylea high dose BLA, giving greater certainty around a potential approval in 2-8 weeks, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron Reports Second Quarter 2023 Financial and Operating Results
- Regeneron reports Q2 adjusted EPS $10.24, consensus $9.84
- Notable companies reporting before tomorrow’s open
- Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
- REGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
